AR050643A1 - Un derivado heterociclico que contiene nitrogeno y un farmaco que contiene el mismo como el ingrediente activo - Google Patents
Un derivado heterociclico que contiene nitrogeno y un farmaco que contiene el mismo como el ingrediente activoInfo
- Publication number
- AR050643A1 AR050643A1 ARP050103795A ARP050103795A AR050643A1 AR 050643 A1 AR050643 A1 AR 050643A1 AR P050103795 A ARP050103795 A AR P050103795A AR P050103795 A ARP050103795 A AR P050103795A AR 050643 A1 AR050643 A1 AR 050643A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituents
- diseases
- group
- heterocyclic group
- atom
- Prior art date
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 title 2
- 239000004480 active ingredient Substances 0.000 title 1
- 229910052757 nitrogen Inorganic materials 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 abstract 8
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 abstract 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 abstract 2
- 206010052779 Transplant rejections Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 210000000056 organ Anatomy 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 208000030507 AIDS Diseases 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010010741 Conjunctivitis Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 1
- 206010062016 Immunosuppression Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 208000024780 Urticaria Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 201000008383 nephritis Diseases 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 206010039083 rhinitis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Los compuestos representados por la formula (1) tienenactividad antagonista contre CCR5, de modo que son utiles para la prevencion y/o tratamiento de enfermedades relacionadas con CCR5, por ejemplo, diversasd enfermedades inflamatorias (asma, nefritis, nefropatía, hepatitis, artritis, artritis reumatoidea, rinitis, conjuntivitis, enfermedad intestinal inflamatoria tal como colitis ulcerativa etc.), enfermedades inmunologicas (enfermedades autoinmunes, rechazo en transpalnte de organos (rechazo de injerto de organo solido, rechaazo de injerto de células de islas pancreáticas en terapia para diabetes, enfermedad de injerto versus huésped etc.), inmunosupresion, soriasis, esclerosis multiple, etc.) enfermedades infecciosas (infeccion con el virus de inmunodeficiencia humana, síndrome de inumunodeficiencia adquirida, infeccion con RSV, etc.), enfermedades alérgicas (dermatitis atopica, urticaria, aspergilosis broncopulmonar alérgica, gastroenteritis eosinofila alérgica, etc.), enfermedades cardiovasculares (arteriosclerosis, lesion por reperfusion isquémica, etc.), síndrome de insuficiencia rspiratoria aguda, infeccion bacteriana acompanante de choque, diabetes, metástasis cancerígena y enfermedades similares. Reivindicacion 1: Un compuesto representado por la formula (1) en dodne R1 representa (1) -N(R1A)SO2-R1B, (2) -SO2NR1CR1D, (3) -COOR1E, (4) -OR1F, (5) -S(O)mR1G, (6) -CONR1HR1J, (7) -NR1KCOR1L, o (8) ciano, en donde m es 0, 1 o 2; R1A, R1B, R1C, R1D, R1E, R1F, R1G, R1H, R1J, R1K y R1L cada uno independientemente representa un átomo de H, un grupo hidrocarburo el cual puede tener un sustituyente o más sustituyentes, o un grupo heterocíclico de 3 a 15 miembros el cual puede tener uno o más sustituyentes, y en donde R1C y R1D o R1H y R1J pueden formar un grupo heterocíclico que contiene N el cual puede tener uno o más sustituyentes junto con un átomo de N al cual se unen; X e Y cada uno independientemente representa un enlace o un espaciador que contiene 1 a 3 'tomos como una cadena principal; el anillo A y el anillo B, los cuales son iguales o diferentes, cada uno representa un grupo carbocíclico o grupo heterocíclico de 3 a 15 miembros el cual puede tener uno o más sustituyentes; el anillo D es un grupo heterocíclico que contiene N de 3 a 15 miembros el cual puede tener uno o más sustituyentes; R2 es (1) un átomo de H; (2) un grupo hidrocarburo el cual puede tener uno o más sustituyentes, (3) un grupo ciano, (4) un grupo hidroxi el cual puede estar protegido, (5) un grupo amino el cual puede tener uno o más sustituyentes, (6) un grupo oxo, (7) un grupo heterocíclico de 3 a 15 miembros el cual puede tener uno o más ustituyentes o (8) =N-OR6, en donde R5 representa un átomo de H o alquilo C1-4, su sal, su N-oxido o su solvato, o su profármaco.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004264855 | 2004-09-13 | ||
| JP2005127359 | 2005-04-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR050643A1 true AR050643A1 (es) | 2006-11-08 |
Family
ID=36060170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050103795A AR050643A1 (es) | 2004-09-13 | 2005-09-12 | Un derivado heterociclico que contiene nitrogeno y un farmaco que contiene el mismo como el ingrediente activo |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US8143404B2 (es) |
| EP (2) | EP1790637B1 (es) |
| JP (1) | JP4894518B2 (es) |
| KR (1) | KR101231466B1 (es) |
| CN (1) | CN101775013A (es) |
| AR (1) | AR050643A1 (es) |
| AU (1) | AU2005283326B2 (es) |
| BR (1) | BRPI0515164A (es) |
| CA (1) | CA2579501C (es) |
| ES (1) | ES2457041T3 (es) |
| IL (1) | IL181783A (es) |
| MA (1) | MA28921B1 (es) |
| MX (1) | MX2007002886A (es) |
| NO (1) | NO20071342L (es) |
| NZ (1) | NZ553696A (es) |
| PE (2) | PE20090123A1 (es) |
| RU (1) | RU2409565C2 (es) |
| SG (1) | SG146673A1 (es) |
| TW (1) | TWI400232B (es) |
| WO (1) | WO2006030925A1 (es) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2517888C (en) | 2003-03-14 | 2012-05-01 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient |
| AU2005214132B9 (en) * | 2004-02-18 | 2009-06-25 | Astrazeneca Ab | Benzamide derivatives and their use as glucokinae activating agents |
| TW200600086A (en) * | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
| JP4894518B2 (ja) | 2004-09-13 | 2012-03-14 | 小野薬品工業株式会社 | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| KR20110084339A (ko) | 2005-07-09 | 2011-07-21 | 아스트라제네카 아베 | 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한 헤테로아릴 벤즈아미드 유도체 |
| US20070066624A1 (en) * | 2005-08-16 | 2007-03-22 | Anormed, Inc. | Chemokine receptor binding compounds |
| WO2007105637A1 (ja) * | 2006-03-10 | 2007-09-20 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| MX2008014672A (es) | 2006-05-19 | 2009-03-09 | Abbott Lab | Derivados de alcano azabiciclico sustituidos con bicicloheterociclo fusionado activos en el sistema nervioso central. |
| TW200813018A (en) | 2006-06-09 | 2008-03-16 | Astrazeneca Ab | Novel compounds |
| CL2007003061A1 (es) * | 2006-10-26 | 2008-08-01 | Astrazeneca Ab | Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2. |
| US10512644B2 (en) | 2007-03-12 | 2019-12-24 | Inheris Pharmaceuticals, Inc. | Oligomer-opioid agonist conjugates |
| US8173666B2 (en) | 2007-03-12 | 2012-05-08 | Nektar Therapeutics | Oligomer-opioid agonist conjugates |
| US8119661B2 (en) | 2007-09-11 | 2012-02-21 | Astrazeneca Ab | Piperidine derivatives and their use as muscarinic receptor modulators |
| WO2009058919A1 (en) * | 2007-10-31 | 2009-05-07 | Smithkline Beecham Corporation | Ccr5 antagonists as therapeutic agents |
| WO2009058921A1 (en) * | 2007-10-31 | 2009-05-07 | Smithkline Beecham Corporation | Ccr5 antagonists as therapeutic agents |
| KR101228378B1 (ko) | 2008-04-11 | 2013-01-31 | 얀센 파마슈티카 엔.브이. | 류코트리엔 α4 하이드롤레이즈의 조정제로서의 티아졸로피리딘-2-일옥시-페닐 및 티아졸로피라진-2-일옥시-페닐 아민 |
| CA2732437C (en) | 2008-08-01 | 2017-11-21 | Ventirx Pharmaceuticals, Inc. | Toll-like receptor agonist formulations and their use |
| EP2324028A2 (en) | 2008-08-04 | 2011-05-25 | AstraZeneca AB | Therapeutic agents 414 |
| US20110237614A1 (en) * | 2008-09-16 | 2011-09-29 | Nektar Therapeutics | Pegylated Opioids with Low Potential for Abuse |
| EP2358683B1 (en) | 2008-11-06 | 2015-04-01 | VentiRx Pharmaceuticals, Inc. | Methods of synthesis of benzazepine derivatives |
| CN102348697B (zh) | 2009-01-12 | 2014-12-10 | 辉瑞股份有限公司 | 磺酰胺衍生物 |
| GB0902434D0 (en) | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Chemical process |
| GB0902406D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Crystalline polymorphic form |
| AR076221A1 (es) * | 2009-04-09 | 2011-05-26 | Astrazeneca Ab | Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad |
| WO2010116177A1 (en) | 2009-04-09 | 2010-10-14 | Astrazeneca Ab | A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity |
| NZ596137A (en) | 2009-05-14 | 2013-08-30 | Janssen Pharmaceutica Nv | Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene a4 hydrolase |
| EP2467380B1 (en) * | 2009-08-18 | 2016-11-30 | Ventirx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
| HUE032626T2 (en) | 2009-08-18 | 2017-10-30 | Ventirx Pharmaceuticals Inc | Toll receptor modulator substituted benzoazepines |
| EP2308484A1 (en) * | 2009-10-06 | 2011-04-13 | Dompé S.p.a. | Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets |
| GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
| ES2532356T3 (es) | 2010-07-09 | 2015-03-26 | Pfizer Limited | N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje |
| UY33337A (es) | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
| TWI586378B (zh) | 2012-03-13 | 2017-06-11 | 瑞斯比維特有限公司 | 新穎醫藥調配物 |
| JO3279B1 (ar) | 2013-03-15 | 2018-09-16 | Respivert Ltd | مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز |
| AR095353A1 (es) | 2013-03-15 | 2015-10-07 | Respivert Ltd | Compuesto |
| TWI642668B (zh) * | 2013-05-27 | 2018-12-01 | 赫孚孟拉羅股份公司 | 新穎３，４－二氫－２ｈ－異喹啉－１－酮及２，３－二氫異吲哚－１－酮化合物 |
| JO3637B1 (ar) | 2015-04-28 | 2020-08-27 | Janssen Sciences Ireland Uc | مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv |
| TW201932470A (zh) | 2017-11-29 | 2019-08-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 具有抗ｒｓｖ活性之吡唑并嘧啶 |
| AU2019216260B2 (en) | 2018-01-31 | 2023-03-02 | Janssen Sciences Ireland Unlimited Company | Cycloalkyl substituted pyrazolopyrimidines having activity against RSV |
| KR20210005569A (ko) | 2018-04-23 | 2021-01-14 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | Rsv에 대한 활성을 갖는 헤테로방향족 화합물 |
| EP3883928A4 (en) | 2018-11-22 | 2022-06-29 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
| CA3121202A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| EP4603143A3 (en) | 2018-12-28 | 2025-11-05 | Mitsubishi Tanabe Pharma Corporation | Crystal of pyrrolidine compound |
| US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| CN120500335A (zh) * | 2022-12-28 | 2025-08-15 | 瑞瑟沃神经科学公司 | Ep2拮抗剂化合物 |
| WO2025034531A1 (en) * | 2023-08-04 | 2025-02-13 | The University Of Vermont And State Agricultural College | Small molecule allosteric modulator to pac1 receptor and uses thereof |
Family Cites Families (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1063744A (en) | 1964-05-25 | 1967-03-30 | American Cyanamid Co | 4-substituted-4'-tertiary aminoalkoxy biphenyls |
| US5169855A (en) | 1990-03-28 | 1992-12-08 | Du Pont Merck Pharmaceutical Company | Piperidine ether derivatives as psychotropic drugs or plant fungicides |
| US5364865A (en) * | 1992-12-30 | 1994-11-15 | Sterling Winthrop Inc. | Phenoxy- and phenoxyalkyl-piperidines as antiviral agents |
| US5486534A (en) * | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
| US5593994A (en) | 1994-09-29 | 1997-01-14 | The Dupont Merck Pharmaceutical Company | Prostaglandin synthase inhibitors |
| IL118469A (en) | 1995-06-15 | 2000-08-13 | Tanabe Seiyaku Co | Naphthalene derivatives their preparation and intermediates thereof |
| AP823A (en) | 1996-03-28 | 2000-04-25 | Glaxo Group Ltd | Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase. |
| WO1998025605A1 (en) | 1996-12-13 | 1998-06-18 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
| ES2162686T3 (es) | 1996-12-19 | 2002-01-01 | Aventis Pharma Inc | Nuevos derivados carboxamidas ciclicos sustituidos por carboxi. |
| ZA985542B (en) | 1997-07-03 | 1999-04-07 | Smithkline Beecham Corp | Substituted benzanilides as CCR5 receptor ligands antiinflammatory agents and antiviral agents |
| EP1003514A4 (en) | 1997-07-25 | 2000-10-11 | Merck & Co Inc | CYCLIC AMINE MODULATORS OF CHEMOKIN RECEPTORS |
| GB9716657D0 (en) | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
| IL125658A0 (en) | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
| EP1020445B1 (en) * | 1997-10-02 | 2008-08-13 | Eisai R&D Management Co., Ltd. | Fused pyridine derivatives |
| AR013669A1 (es) | 1997-10-07 | 2001-01-10 | Smithkline Beecham Corp | Compuestos y metodos |
| JP4321737B2 (ja) | 1997-12-17 | 2009-08-26 | 塩野義製薬株式会社 | 新規ピリジン化合物 |
| CN1282243A (zh) | 1997-12-19 | 2001-01-31 | 武田药品工业株式会社 | 用于拮抗ccr5的含n－酰苯胺衍生物的药物组合物 |
| JP2002501898A (ja) | 1998-02-02 | 2002-01-22 | メルク エンド カムパニー インコーポレーテッド | ケモカイン受容体活性の環状アミン調節剤 |
| GB9803226D0 (en) | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
| WO1999055324A1 (en) | 1998-04-27 | 1999-11-04 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| WO1999055330A1 (en) | 1998-04-27 | 1999-11-04 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| CA2338697A1 (en) | 1998-07-28 | 2000-02-10 | Smithkline Beecham Corporation | Compounds and methods |
| EP1100495A4 (en) | 1998-07-28 | 2002-09-25 | Smithkline Beecham Corp | PROPENAMIDES AS CCR5 MODULATORS |
| CN1310621A (zh) | 1998-07-28 | 2001-08-29 | 史密丝克莱恩比彻姆公司 | 取代的n－酰苯胺化合物和方法 |
| CA2337307A1 (en) | 1998-08-20 | 2000-03-02 | Osamu Nishimura | Quaternary ammonium salts and their use |
| WO2000021916A1 (fr) | 1998-10-15 | 2000-04-20 | Takeda Chemical Industries, Ltd. | Procede de preparation de derives d'amine |
| WO2000027835A1 (en) | 1998-11-09 | 2000-05-18 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| WO2000027843A1 (en) | 1998-11-09 | 2000-05-18 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| ATE280157T1 (de) | 1998-11-17 | 2004-11-15 | Hoffmann La Roche | 4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii |
| JP3421323B2 (ja) | 1998-11-20 | 2003-06-30 | エフ．ホフマン−ラ ロシュ アーゲー | ピペリジンｃｃｒ−３受容体拮抗薬 |
| CA2350903A1 (en) | 1998-11-20 | 2000-06-02 | F. Hoffmann-La Roche Ag | Pyrrolidine derivatives-ccr-3 receptor antagonists |
| CN1149214C (zh) | 1998-12-04 | 2004-05-12 | 东丽株式会社 | 三唑并衍生物和含有它们作为有效组分的趋化因子抑制剂 |
| EP1158980B1 (en) | 1998-12-18 | 2005-08-24 | Bristol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| AU2056800A (en) | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | Heterocyclic piperidines as modulators of chemokine receptor activity |
| AU3126700A (en) | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| US6441001B1 (en) | 1998-12-18 | 2002-08-27 | Bristol-Myers Squibb Pharma Company | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity |
| US6444686B1 (en) | 1998-12-18 | 2002-09-03 | Brsitol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| CA2350730A1 (en) | 1998-12-18 | 2000-06-22 | George V. Delucca | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| WO2000035449A1 (en) | 1998-12-18 | 2000-06-22 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| WO2000037455A1 (en) | 1998-12-21 | 2000-06-29 | Takeda Chemical Industries, Ltd. | Benzothiepin-anilide derivatives, their production and their use for antagonizing ccr-5 |
| PE20001420A1 (es) | 1998-12-23 | 2000-12-18 | Pfizer | Moduladores de ccr5 |
| US7217714B1 (en) | 1998-12-23 | 2007-05-15 | Agouron Pharmaceuticals, Inc. | CCR5 modulators |
| EP1013276A1 (en) | 1998-12-23 | 2000-06-28 | Pfizer Inc. | Aminoazacycloalkanes as CCR5 modulators |
| ES2219104T3 (es) | 1998-12-30 | 2004-11-16 | Smithkline Beecham Corporation | Compuestos y procedimientos. |
| EA200100774A1 (ru) | 1999-01-13 | 2002-02-28 | Милленниум Фамэсьютикэлс, Инк. | Гетероциклические производные с функциональными группами (варианты), фармацевтическая композиция и комбинация, способ модулирования активности рецептора хемокина (варианты), способ профилактики инфицирования вич и лечения инфекции вич, замедления проявления спид и лечения спид, способ лечения воспалительных процессов |
| WO2000041685A1 (en) | 1999-01-19 | 2000-07-20 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| JP2002535256A (ja) | 1999-01-25 | 2002-10-22 | スミスクライン・ビーチャム・コーポレイション | 化合物および方法 |
| GB9902452D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902455D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902459D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902461D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902453D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| JP2000309598A (ja) | 1999-02-25 | 2000-11-07 | Takeda Chem Ind Ltd | 多剤結合型新規化合物、その製造法および用途 |
| US6372764B1 (en) | 1999-03-02 | 2002-04-16 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| AU3386400A (en) | 1999-03-02 | 2000-09-21 | Merck & Co., Inc. | 3-alkyl substituted pyrrolidine modulators of chemokine receptor activity |
| US6303593B1 (en) | 1999-03-02 | 2001-10-16 | Merck & Co., Inc. | 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity |
| AU3386500A (en) | 1999-03-02 | 2000-09-21 | Merck & Co., Inc. | 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity |
| WO2000053172A1 (en) | 1999-03-08 | 2000-09-14 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| JP2002538203A (ja) | 1999-03-10 | 2002-11-12 | スミスクライン・ビーチャム・コーポレイション | 化合物および方法 |
| AU2942000A (en) | 1999-03-11 | 2000-09-28 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivatives |
| JP2003524620A (ja) | 1999-03-24 | 2003-08-19 | アノーメッド インコーポレイティド | ケモカインレセプター結合複素環化合物 |
| SK11822001A3 (sk) | 1999-03-26 | 2002-09-10 | Astrazeneca Ab | Modulátory chemokínovej aktivity, spôsoby ich prípravy, farmaceutické kompozície s ich obsahom a ich použitie v terapii |
| US6248755B1 (en) | 1999-04-06 | 2001-06-19 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| US6498161B1 (en) | 1999-04-06 | 2002-12-24 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| US6265434B1 (en) | 1999-04-06 | 2001-07-24 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| US6399619B1 (en) | 1999-04-06 | 2002-06-04 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| US6358697B2 (en) | 1999-04-21 | 2002-03-19 | Children's Hospital Medical Center | Intracellular pharmaceutical targeting |
| WO2000066551A1 (en) | 1999-04-28 | 2000-11-09 | Takeda Chemical Industries, Ltd. | Cyclic amide compounds, process for the preparation of the same and uses thereof |
| AU4692400A (en) | 1999-05-03 | 2000-11-17 | Smithkline Beecham Corporation | Cxcr-4 receptor antagonists - thrombopoietin mimetics |
| US6391865B1 (en) | 1999-05-04 | 2002-05-21 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
| ES2244437T3 (es) | 1999-05-04 | 2005-12-16 | Schering Corporation | Derivados de piperazina utiles como antagonistas de ccr5. |
| JP2002543144A (ja) | 1999-05-04 | 2002-12-17 | シェーリング コーポレイション | ＰＥＧ化インターフェロンαＣＣＲ５アンタゴニスト併用ＨＩＶ療法 |
| EP1175402B1 (en) | 1999-05-04 | 2005-07-20 | Schering Corporation | Piperidine derivatives useful as ccr5 antagonists |
| AU4145200A (en) | 1999-05-07 | 2000-11-21 | Takeda Chemical Industries Ltd. | Cyclic compounds and uses thereof |
| AU4796700A (en) | 1999-05-13 | 2000-12-05 | Dupont Pharmaceuticals Research Laboratories, Inc. | Ureido-substituted cyclic amine derivatives and their use as drug |
| ES2250132T3 (es) | 1999-05-18 | 2006-04-16 | Teijin Limited | Remedios preventivos para enfermedades asociadas a quimioquinas. |
| JP2003510248A (ja) | 1999-05-27 | 2003-03-18 | セルテク バイオテクノロジーズ インコーポレイテッド | ケモカイン受容体ｃｃｒ３アンタゴニスト |
| US6165261A (en) | 1999-06-10 | 2000-12-26 | Ergon, Inc. | Water-resistant gypsum composition |
| WO2001009088A1 (en) | 1999-07-28 | 2001-02-08 | Kirin Beer Kabushiki Kaisha | Urea derivatives as inhibitors of ccr-3 receptor |
| SE9902987D0 (sv) | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
| EP1216232B1 (en) | 1999-08-27 | 2006-10-11 | ChemoCentryx Inc | Heterocyclic compounds and methods for modulating cxcr3 function |
| FR2798367B1 (fr) * | 1999-09-15 | 2001-11-23 | Valois Sa | Joint de soupape pour valve doseuse |
| TWI224597B (en) | 1999-12-03 | 2004-12-01 | Ono Pharmaceutical Co | Triazaspiro[5.5]undecane derivatives and a medicine containing the derivatives as an active ingredient |
| GB0011838D0 (en) | 2000-05-17 | 2000-07-05 | Astrazeneca Ab | Chemical compounds |
| CN1474810A (zh) | 2000-09-14 | 2004-02-11 | ���鹫˾ | 取代脲,神经肽yy5受体拮抗剂 |
| US6894063B2 (en) | 2000-09-14 | 2005-05-17 | Schering Corporation | Substituted urea neuropeptide Y Y5 Receptor antagonists |
| UY26942A1 (es) | 2000-09-20 | 2002-04-26 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| AU2001297717B2 (en) | 2000-12-11 | 2006-02-23 | Amgen Inc. | CXCR3 antagonists |
| GB0100102D0 (en) | 2001-01-03 | 2001-02-14 | Syngenta Participations Ag | Organic compounds |
| CA2440238C (en) | 2001-03-16 | 2011-09-13 | Abbott Laboratories | Novel amines as histamine-3 receptor ligands and their therapeutic applications |
| CN1291988C (zh) | 2001-03-19 | 2006-12-27 | 小野药品工业株式会社 | 三氮杂螺[5,5]十一烷衍生物及包含其作为活性成分的药物组合物 |
| CZ20032636A3 (cs) * | 2001-03-29 | 2003-12-17 | Schering Corporation | Látky antagonizující CCR5 |
| GB0108099D0 (en) * | 2001-03-30 | 2001-05-23 | Hoffmann La Roche | Aminopiperidine derivatives |
| WO2002083628A1 (en) | 2001-04-13 | 2002-10-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-disubstituted benzo-fused compounds |
| US6495569B1 (en) | 2001-04-19 | 2002-12-17 | Millennium Pharmaceuticals, Inc. | Imidazolidine compounds |
| US6469002B1 (en) | 2001-04-19 | 2002-10-22 | Millennium Pharmaceuticals, Inc. | Imidazolidine compounds |
| ATE338035T1 (de) | 2001-06-05 | 2006-09-15 | Boehringer Ingelheim Pharma | 1,4-disubstituierte benzokondensierte cycloalkyl harnstoffverbindungen |
| HRP20030834A2 (en) | 2001-06-20 | 2004-08-31 | Pfizer Prod Inc | Novel sulfonic acid derivatives |
| US6867221B2 (en) | 2001-08-30 | 2005-03-15 | Kowa Co., Ltd. | Cyclic amine compounds and pharmaceutical composition containing the same |
| WO2003037271A2 (en) | 2001-10-30 | 2003-05-08 | Millennium Pharmaceuticals,Inc. | Compounds, pharmaceutical compositions and methods of use therefor |
| HUP0401924A3 (en) | 2001-11-14 | 2009-07-28 | Schering Corp | Cannabinoid receptor ligands, their use and pharmaceutical compositions containing them |
| TW200302717A (en) * | 2002-02-06 | 2003-08-16 | Schering Corp | Novel gamma secretase inhibitors |
| GB0203994D0 (en) | 2002-02-20 | 2002-04-03 | Celltech R&D Ltd | Chemical compounds |
| US20030195192A1 (en) * | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
| JP2005530813A (ja) | 2002-06-03 | 2005-10-13 | スミスクライン・ビーチャム・コーポレイション | イミダゾリウムｃｘｃｒ３阻害剤 |
| AU2003242252A1 (en) * | 2002-06-07 | 2003-12-22 | Kyowa Hakko Kogyo Co., Ltd. | Bicyclic pyrimidine derivatives |
| CN1688577A (zh) | 2002-09-18 | 2005-10-26 | 小野药品工业株式会社 | 三氮杂螺[5.5]十一烷衍生物及以它为活性成分的药物 |
| WO2004041279A1 (en) | 2002-10-30 | 2004-05-21 | Merck & Co., Inc. | Gamma-aminoamide modulators of chemokine receptor activity |
| US7342115B2 (en) | 2002-11-08 | 2008-03-11 | Neurogen Corporation | 3-substituted-6-aryl pyridines |
| JPWO2004046110A1 (ja) | 2002-11-15 | 2006-03-16 | アステラス製薬株式会社 | メラニン凝集ホルモン受容体拮抗剤 |
| JP4666256B2 (ja) | 2002-12-10 | 2011-04-06 | 小野薬品工業株式会社 | 含窒素複素環化合物およびその医薬用途 |
| JP2004256531A (ja) | 2003-02-07 | 2004-09-16 | Takeda Chem Ind Ltd | 三環性化合物、その製造法および用途 |
| GB0305426D0 (en) | 2003-03-08 | 2003-04-16 | Glaxo Group Ltd | Novel compounds |
| CA2517888C (en) * | 2003-03-14 | 2012-05-01 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient |
| ATE512957T1 (de) * | 2003-04-24 | 2011-07-15 | Merck Sharp & Dohme | Hemmer der akt aktivität |
| WO2005023771A1 (ja) | 2003-09-05 | 2005-03-17 | Ono Pharmaceutical Co., Ltd. | ケモカインレセプターアンタゴニストおよびその医薬用途 |
| JP4894518B2 (ja) | 2004-09-13 | 2012-03-14 | 小野薬品工業株式会社 | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| JP2007063268A (ja) | 2005-08-05 | 2007-03-15 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| US20070066624A1 (en) | 2005-08-16 | 2007-03-22 | Anormed, Inc. | Chemokine receptor binding compounds |
| WO2007105637A1 (ja) | 2006-03-10 | 2007-09-20 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
-
2005
- 2005-09-12 JP JP2006535240A patent/JP4894518B2/ja not_active Expired - Fee Related
- 2005-09-12 KR KR1020077008318A patent/KR101231466B1/ko not_active Expired - Fee Related
- 2005-09-12 PE PE2008001407A patent/PE20090123A1/es not_active Application Discontinuation
- 2005-09-12 CN CN201010126265A patent/CN101775013A/zh active Pending
- 2005-09-12 BR BRPI0515164-3A patent/BRPI0515164A/pt not_active IP Right Cessation
- 2005-09-12 WO PCT/JP2005/017209 patent/WO2006030925A1/ja not_active Ceased
- 2005-09-12 AR ARP050103795A patent/AR050643A1/es not_active Application Discontinuation
- 2005-09-12 US US11/662,639 patent/US8143404B2/en not_active Expired - Fee Related
- 2005-09-12 CA CA2579501A patent/CA2579501C/en not_active Expired - Fee Related
- 2005-09-12 EP EP05785808.6A patent/EP1790637B1/en not_active Expired - Lifetime
- 2005-09-12 TW TW094131265A patent/TWI400232B/zh not_active IP Right Cessation
- 2005-09-12 EP EP12186689A patent/EP2546234A1/en not_active Withdrawn
- 2005-09-12 ES ES05785808.6T patent/ES2457041T3/es not_active Expired - Lifetime
- 2005-09-12 MX MX2007002886A patent/MX2007002886A/es active IP Right Grant
- 2005-09-12 RU RU2007113814/04A patent/RU2409565C2/ru not_active IP Right Cessation
- 2005-09-12 NZ NZ553696A patent/NZ553696A/en not_active IP Right Cessation
- 2005-09-12 SG SG200807030-2A patent/SG146673A1/en unknown
- 2005-09-12 PE PE2005001056A patent/PE20060598A1/es not_active Application Discontinuation
- 2005-09-12 AU AU2005283326A patent/AU2005283326B2/en not_active Ceased
-
2007
- 2007-03-07 IL IL181783A patent/IL181783A/en not_active IP Right Cessation
- 2007-03-12 NO NO20071342A patent/NO20071342L/no not_active Application Discontinuation
- 2007-04-06 MA MA29806A patent/MA28921B1/fr unknown
-
2011
- 2011-01-28 US US13/016,849 patent/US8410276B2/en not_active Expired - Fee Related
-
2012
- 2012-11-21 US US13/682,784 patent/US8604207B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR050643A1 (es) | Un derivado heterociclico que contiene nitrogeno y un farmaco que contiene el mismo como el ingrediente activo | |
| EA200870344A1 (ru) | Азотсодержащее гетероциклическое производное и фармацевтическое средство, включающее такое производное в качестве активного ингредиента | |
| NO20054244L (no) | Nitrogeninneholdende heterocykliske derivater og legemidler inneholdende de samme som den aktive bestanddel | |
| ES2630705T3 (es) | Compuestos de piridilo sustituidos con triazolilo útiles como inhibidores de cinasas | |
| Ji et al. | Design, synthesis and evaluation of novel quinazoline-2, 4-dione derivatives as chitin synthase inhibitors and antifungal agents | |
| NO20065694L (no) | Indolderivat med piperidinring | |
| NO20072688L (no) | Aminpyridinderivat med aurora A-selektiv inhiberende virkning | |
| NO20075768L (no) | Hydroksybenzamidderivater og deres anvendelse som inhibitorer av HSP90 | |
| EP1541574A4 (en) | TRIAZASPIRO DERIVATIVES 5.5 | UNDECANS AND DRUGS CONTAINING THEM AS AN ACTIVE INGREDIENT | |
| PE20121159A1 (es) | DERIVADOS DE PIRIDINA, PIRAZINA Y QUINOLINA COMO INHIBIDORES DE LA FOSFOINOSITIDA 3 CINASA Y LA mTOR | |
| NO20085140L (no) | Nye indazolderivater som har spiro ringstruktur i sidekjede | |
| AR071763A1 (es) | Pirazoles trisustituidos, composiciones farmaceuticas que los contienen, y usos de los mismos en el tratamiento de trastornos neurologicos y psiquiatricos | |
| NO20063446L (no) | Tiazolderivater | |
| AR060421A1 (es) | Derivados de nitrocatecol sustituidos | |
| NO20075384L (no) | Tiadiazolsubstituerte kumarinderivater og deres anvendelse som leukotrienbiosynteseinhibitorer. | |
| AR057770A1 (es) | Inhibidores de la p38-map-quinasa y composicion farmaceutica | |
| PE20090293A1 (es) | COMPUESTO DERIVADO DE 3-(IMIDAZOLIL)-PIRAZOLO[3,4-b]PIRIDINAS, PROCEDIMIENTO DE PREPARACION Y COMPOSICIONES FARMACEUTICAS | |
| ECSP088378A (es) | Derivados de piperazina útiles como antagonistas de ccr5 | |
| UA102073C2 (ru) | Улучшение свойств органических соединений или характеристик, связанных с органическими соединениями | |
| CA2626767A1 (en) | Heterocyclic substituted pyridine derivatives and antifungal agent containing same | |
| PE20061078A1 (es) | Derivados de piridotienopirimidina como inhibidores de la fosfodiesterasa 4 (pde4) | |
| AR077898A1 (es) | Metilpirrolopirimidincarboxamidas | |
| AR054587A1 (es) | Derivados de quinolina antibacterianos | |
| NO20091779L (no) | Nye indolforbindelser en prosess for deres fremstilling og farmasoytiske sammensetninger som inneholder dem | |
| EP1621540A4 (en) | HETEROCYCLIC COMPOUNDS CONTAINING NITROGEN AND USE THEREOF |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |